Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1693-1706

  Zhang, Jinsong ^a   Alam, S Munir ^a   Bouton Verville, Hilary ^a   Chen, Yao ^a   Newman, Amanda ^a   Stewart, Shelley ^a   Jaeger, Frederick H ^a   Montefiori, David C ^a   Dennison, S Moses ^a   Haynes, Barton F ^a   Verkoczy, Laurent ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT JRFL GLYCOPROTEIN GP 41; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CELL HETEROGENEITY; CONTROLLED STUDY; FEMALE; HAPLOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOASSAY; IMMUNOMODULATION; MEMBRANE BIOLOGY; MEMBRANE PROXIMAL EXTERNAL REGION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CD40 LIGAND; CELL PROLIFERATION; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84896703681     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302511     Document Type: Article

References (81)

1. McElrath, M. J., and B. F. Haynes. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
2. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6: 207-210.
3. Hessell, A. J., E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D. N. Forthal, W. C. Koff, D. I. Watkins, and D. R. Burton. 2009. Broadly neutralizing human anti-HIVantibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5: e1000433.
4. Hessell, A. J., E. G. Rakasz, D. M. Tehrani, M. Huber, K. L. Weisgrau, G. Landucci, D. N. Forthal, W. C. Koff, P. Poignard, D. I. Watkins, and D. R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membraneproximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84: 1302-1313.
5. Balazs, A. B., J. Chen, C. M. Hong, D. S. Rao, L. Yang, and D. Baltimore. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
6. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10: 11-23.
7. Haynes, B. F., G. Kelsoe, S. C. Harrison, and T. B. Kepler. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30: 423-433.
8. Mikell, I., D. N. Sather, S. A. Kalams, M. Altfeld, G. Alter, and L. Stamatatos. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7: e1001251.
9. Stamatatos, L., L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15: 866-870.
10. Verkoczy, L., G. Kelsoe, M. A. Moody, and B. F. Haynes. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23: 383-390.
11. Cardoso, R. M., M. B. Zwick, R. L. Stanfield, R. Kunert, J. M. Binley, H. Katinger, D. R. Burton, and I. A. Wilson. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusionassociated motif in gp41. Immunity 22: 163-173.
12. Huang, J., G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, H. Imamichi, R. T. Bailer, B. Chakrabarti, S. K. Sharma, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
13. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67: 6642-6647.
14. Ofek, G., M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, and P. D. Kwong. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78: 10724-10737.
15. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17: 1757-1765.
16. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75: 10892-10905.
17. Arnold, G. F., P. K. Velasco, A. K. Holmes, T. Wrin, S. C. Geisler, P. Phung, Y. Tian, D. A. Resnick, X. Ma, T. M. Mariano, et al. 2009. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J. Virol. 83: 5087-5100.
18. Frey, G., H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, and B. Chen. 2008. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 105: 3739-3744.
19. Guenaga, J., P. Dosenovic, G. Ofek, D. Baker, W. R. Schief, P. D. Kwong, G. B. Karlsson Hedestam, and R. T. Wyatt. 2011. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6: e16074.
20. Montero, M., N. Gulzar, K. A. Klaric, J. E. Donald, C. Lepik, S. Wu, S. Tsai, J. P. Julien, A. J. Hessell, S. Wang, et al. 2012. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J. Virol. 86: 2930-2941.
21. Ofek, G., F. J. Guenaga, W. R. Schief, J. Skinner, D. Baker, R. Wyatt, and P. D. Kwong. 2010. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 107: 17880-17887.
22. Zhou, M., I. Kostoula, B. Brill, E. Panou, M. Sakarellos-Daitsiotis, and U. Dietrich. 2012. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine 30: 1911-1916.
23. Denner, J. 2011. Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralizing antibodies. Hum. Vaccin. 7(Suppl): 4-9.
24. McCoy, L. E., and R. A. Weiss. 2013. Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 210: 209-223.
25. Montero, M., N. E. van Houten, X. Wang, and J. K. Scott. 2008. The membraneproximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72: 54-84.
26. Haynes, B. F., M. A. Moody, L. Verkoczy, G. Kelsoe, and S. M. Alam. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14: 59-67.
27. Haynes, B. F., J. Fleming, E. W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
28. Verkoczy, L., Y. Chen, H. Bouton-Verville, J. Zhang, M. Diaz, J. Hutchinson, Y. B. Ouyang, S. M. Alam, T. M. Holl, K. K. Hwang, et al. 2011. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J. Immunol. 187: 3785-3797.
29. Verkoczy, L., M. Diaz, T. M. Holl, Y. B. Ouyang, H. Bouton-Verville, S. M. Alam, H. X. Liao, G. Kelsoe, and B. F. Haynes. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. USA 107: 181-186.
30. Nemazee, D. A., and K. Bürki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337: 562-566.
31. Erikson, J., M. Z. Radic, S. A. Camper, R. R. Hardy, C. Carmack, and M. Weigert. 1991. Expression of anti-DNA immunoglobulin transgenes in nonautoimmune mice. Nature 349: 331-334.
32. Chen, C., Z. Nagy, M. Z. Radic, R. R. Hardy, D. Huszar, S. A. Camper, and M. Weigert. 1995. The site and stage of anti-DNA B-cell deletion. Nature 373: 252-255.
33. Chen, Y., J. Zhang, K.-K. Hwang, H. Bouton-Verville, S.-M. Xia, A. Newman, Y.-B. Ouyang, B. F. Haynes, and L. Verkoczy. 2013. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol. 191: 1260-1275.
34. Cambier, J. C., S. B. Gauld, K. T. Merrell, and B. J. Vilen. 2007. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat. Rev. Immunol. 7: 633-643.
35. Goodnow, C. C. 1992. B-cell tolerance. Curr. Opin. Immunol. 4: 703-710.
36. Verkoczy, L., Y. Chen, J. Zhang, H. Bouton-Verville, A. Newman, B. Lockwood, R. M. Scearce, D. C. Montefiori, S. M. Dennison, S. M. Xia, et al. 2013. Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knockin Mice: selection against MPER-associated autoreactivity limits T-dependent responses. J. Immunol. 191: 2538-2550.
37. Dennison, S. M., L. L. Sutherland, F. H. Jaeger, K. M. Anasti, R. Parks, S. Stewart, C. Bowman, S. M. Xia, R. Zhang, X. Shen, et al. 2011. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS ONE 6: e27824.
38. Alam, S. M., M. McAdams, D. Boren, M. Rak, R. M. Scearce, F. Gao, Z. T. Camacho, D. Gewirth, G. Kelsoe, P. Chen, and B. F. Haynes. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178: 4424-4435.
39. Alam, S. M., M. Morelli, S. M. Dennison, H. X. Liao, R. Zhang, S. M. Xia, S. Rits-Volloch, L. Sun, S. C. Harrison, B. F. Haynes, and B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 106: 20234-20239.
40. Klein, F., R. Diskin, J. F. Scheid, C. Gaebler, H. Mouquet, I. S. Georgiev, M. Pancera, T. Zhou, R. B. Incesu, B. Z. Fu, et al. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153: 126-138.
41. Alam, S. M., R. M. Scearce, R. J. Parks, K. Plonk, S. G. Plonk, L. L. Sutherland, M. K. Gorny, S. Zolla-Pazner, S. Vanleeuwen, M. A. Moody, et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82: 115-125.
42. Shen, X., S. M. Dennison, P. Liu, F. Gao, F. Jaeger, D. C. Montefiori, L. Verkoczy, B. F. Haynes, S. M. Alam, and G. D. Tomaras. 2010. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. USA 107: 5972-5977.
43. Nicely, N. I., S. M. Dennison, L. Spicer, R. M. Scearce, G. Kelsoe, Y. Ueda, H. Chen, H. X. Liao, S. M. Alam, and B. F. Haynes. 2010. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat. Struct. Mol. Biol. 17: 1492-1494.
44. Schief, W. R., Y. E. A. Ban, and L. Stamatatos. 2009. Challenges for structurebased HIV vaccine design. Curr. Opin. HIV AIDS 4: 431-440.
45. Liao, H. X., X. Chen, S. Munshaw, R. Zhang, D. J. Marshall, N. Vandergrift, J. F. Whitesides, X. Lu, J. S. Yu, K. K. Hwang, et al. 2011. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208: 2237-2249.
46. Tomaras, G. D., N. L. Yates, P. Liu, L. Qin, G. G. Fouda, L. L. Chavez, A. C. Decamp, R. J. Parks, V. C. Ashley, J. T. Lucas, et al. 2008. Initial Bcell responses to transmitted human immunodeficiency virus type 1: virionbinding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82: 12449-12463.
47. McMichael, A. J., and B. F. Haynes. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13: 423-427.
48. Verkoczy, L., M. A. Moody, T. M. Holl, H. Bouton-Verville, R. M. Scearce, J. Hutchinson, S. M. Alam, G. Kelsoe, and B. F. Haynes. 2009. Functional, nonclonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS ONE 4: e7215.
49. Seaman, M. S., H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy, A. Giri, R. T. Coffey, L. Harris, B. Wood, M. G. Daniels, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
50. Banerjee, K., S. Andjelic, P. J. Klasse, Y. Kang, R. W. Sanders, E. Michael, R. J. Durso, T. J. Ketas, W. C. Olson, and J. P. Moore. 2009. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389: 108-121.
51. Daly, L. M., P. A. Johnson, G. Donnelly, C. Nicolson, J. Robertson, and K. H. Mills. 2005. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine 23: 963-974.
52. Gorse, G. J., L. Corey, G. B. Patel, M. Mandava, R. H. Hsieh, T. J. Matthews, M. C. Walker, M. J. McElrath, P. W. Berman, M. M. Eibl, and R. B. Belshe; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 1999. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses 15: 115-132.
53. Jankovic, D., P. Caspar, M. Zweig, M. Garcia-Moll, S. D. Showalter, F. R. Vogel, and A. Sher. 1997. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159: 2409-2417.
54. Dennison, S. M., S. M. Stewart, K. C. Stempel, H.-X. Liao, B. F. Haynes, and S. M. Alam. 2009. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J. Virol. 83: 10211-10223.
55. Maggi, E., M. Mazzetti, A. Ravina, F. Annunziato, M. de Carli, M. P. Piccinni, R. Manetti, M. Carbonari, A. M. Pesce, G. del Prete, et al. 1994. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 265: 244-248.
56. Clerici, M., and G. M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15: 575-581.
57. Benjamin, D. C., J. A. Berzofsky, I. J. East, F. R. Gurd, C. Hannum, S. J. Leach, E. Margoliash, J. G. Michael, A. Miller, E. M. Prager, et al. 1984. The antigenic structure of proteins: a reappraisal. Annu. Rev. Immunol. 2: 67-101.
58. Bezofsky, J. A. 1983. T-B reciprocity. An Ia-restricted epitope-specific circuit regulating T cell-B cell interaction and antibody specificity. Surv. Immunol. Res. 2: 223-229.
59. Hachimura, S., A. Enomoto, and S. Kaminogawa. 1990. Relative positioning of the T cell and B cell determinants on an immunogenic peptide: its influence on antibody response. Biochem. Biophys. Res. Commun. 169: 803-808.
60. Ozaki, S., and J. A. Berzofsky. 1987. Antibody conjugates mimic specific B cell presentation of antigen: relationship between T and B cell specificity. J. Immunol. 138: 4133-4142.
61. Unanue, E. R., and P. M. Allen. 1987. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 236: 551-557.
62. Kovac, Z., and R. H. Schwartz. 1985. The molecular basis of the requirement for antigen processing of pigeon cytochrome c prior to T cell activation. J. Immunol. 134: 3233-3240.
63. Kurisaki, J., H. Atassi, and M. Z. Atassi. 1986. T cell recognition of ragweed allergen Ra3: localization of the full T cell recognition profile by synthetic overlapping peptides representing the entire protein chain. Eur. J. Immunol. 16: 236-240.
64. Nicholas, J. A., M. A. Mitchell, M. E. Levely, K. L. Rubino, J. H. Kinner, N. K. Harn, and C.W. Smith. 1988. Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus. J. Virol. 62: 4465-4473.
65. Comerford, S. A., D. J. McCance, G. Dougan, and J. P. Tite. 1991. Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. J. Virol. 65: 4681-4690.
66. Barnett, B. C., C. M. Graham, D. S. Burt, J. J. Skehel, and D. B. Thomas. 1989. The immune response of BALB/c mice to influenza hemagglutinin: commonality of the B cell and T cell repertoires and their relevance to antigenic drift. Eur. J. Immunol. 19: 515-521.
67. Graham, C. M., B. C. Barnett, I. Hartlmayr, D. S. Burt, R. Faulkes, J. J. Skehel, and D. B. Thomas. 1989. The structural requirements for class II (I-Ad)-restricted T cell recognition of influenza hemagglutinin: B cell epitopes define T cell epitopes. Eur. J. Immunol. 19: 523-528.
68. Harris, D. P., H. M. Vordermeier, A. Arya, K. Bogdan, C. Moreno, and J. Ivanyi. 1996. Immunogenicity of peptides for B cells is not impaired by overlapping T-cell epitope topology. Immunology 88: 348-354.
69. Sette, A., and R. Rappuoli. 2010. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33: 530-541.
70. Dromey, J. A., S. M. Weenink, G. H. Peters, J. Endl, P. J. Tighe, I. Todd, and M. R. Christie. 2004. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J. Immunol. 172: 4084-4090.
71. Haynes, B. F., L. O. Arthur, P. Frost, T. J. Matthews, A. J. Langlois, T. J. Palker, M. K. Hart, R. M. Scearce, D. M. Jones, C. McDanal, et al. 1993. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. J. Exp. Med. 177: 717-727.
72. Lata, S., M. Bhasin, and G. P. Raghava. 2007. Application of machine learning techniques in predicting MHC binders. Methods Mol. Biol. 409: 201-215.
73. Sette, A., M. Moutaftsi, J. Moyron-Quiroz, M. M. McCausland, D. H. Davies, R. J. Johnston, B. Peters, M. Rafii-El-Idrissi Benhnia, J. Hoffmann, H. P. Su, et al. 2008. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28: 847-858.
74. Gustavsson, S., S. Hjulström-Chomez, B. M. Lidström, N. Ahlborg, R. Andersson, and B. Heyman. 1998. Impaired antibody responses in H-2Ab mice. J. Immunol. 161: 1765-1771.
75. Yang, G., T. M. Holl, Y. Liu, Y. Li, X. Lu, N. I. Nicely, T. B. Kepler, S.M. Alam, H. X. Liao, D.W. Cain, et al. 2013. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210: 241-256.
76. Ferre, A. L., P. W. Hunt, D. H. McConnell, M. M. Morris, J. C. Garcia, R. B. Pollard, H. F. Yee, Jr., J. N. Martin, S. G. Deeks, and B. L. Shacklett. 2010. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J. Virol. 84: 11020-11029.
77. Karasavvas, N., E. Billings, M. Rao, C. Williams, S. Zolla-Pazner, R. T. Bailer, R. A. Koup, S. Madnote, D. Arworn, X. Shen, et al; MOPH TAVEG Collaboration. 2012. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 28: 1444-1457.
78. de Souza, M. S., S. Ratto-Kim, W. Chuenarom, A. Schuetz, S. Chantakulkij, B. Nuntapinit, A. Valencia-Micolta, D. Thelian, S. Nitayaphan, P. Pitisuttithum, et al; Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Collaborators. 2012. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 188: 5166-5176.
79. Paris, R., S. Bejrachandra, P. Thongcharoen, S. Nitayaphan, P. Pitisuttithum, A. Sambor, S. Gurunathan, D. Francis, S. Ratto-Kim, C. Karnasuta, et al. 2012. HLA class II restriction of HIV-1 clade-specific responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX B/E. Vaccine 30: 832-836.
80. Wang, P., J. Sidney, C. Dow, B. Mothé, A. Sette, and B. Peters. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLOS Comput. Biol. 4: e1000048.
81. Liao, H. X., L. L. Sutherland, S. M. Xia, M. E. Brock, R. M. Scearce, S. Vanleeuwen, S. M. Alam, M. McAdams, E. A. Weaver, Z. Camacho, et al. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268-282.